Edition:
India

STAAR Surgical Co (STAA.OQ)

STAA.OQ on NASDAQ Stock Exchange Global Market

15.90USD
23 Jan 2018
Change (% chg)

$-0.05 (-0.31%)
Prev Close
$15.95
Open
$15.85
Day's High
$15.95
Day's Low
$15.55
Volume
35,116
Avg. Vol
38,425
52-wk High
$17.60
52-wk Low
$8.95

Chart for

About

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in... (more)

Overall

Beta: 1.09
Market Cap(Mil.): $563.19
Shares Outstanding(Mil.): 41.11
Dividend: --
Yield (%): --

Financials

BRIEF-STAAR Surgical Sees ‍Double Digit Revenue Growth In FY 2018 Over 2017

* STAAR SURGICAL SEES ‍DOUBLE DIGIT REVENUE GROWTH IN FULL YEAR 2018 OVER 2017 AND ICL UNIT GROWTH RANGE 15% TO 20% FOR 2018​ Source text (http://bit.ly/2AFxyde) Further company coverage:

08 Jan 2018

BRIEF-Staar Surgical reports Q3 earnings per share $0.03

* Q3 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S

09 Nov 2017

BRIEF-Staar surgical appoints Scott Barnes, M.D. as chief medical officer

* Staar surgical appoints Scott Barnes, M.D. as chief medical officer Source text for Eikon: Further company coverage:

02 Oct 2017

BRIEF-Staar Surgical names Deborah Andrews as CFO

* Deborah Andrews, interim CFO, has agreed to resume her role as Chief Financial Officer for company​ Source text for Eikon: Further company coverage:

28 Sep 2017

BRIEF-STAAR Surgical, Seoul/Busan BalGeunSeSang eye clinic announce strategic cooperation agreement

* STAAR Surgical and Seoul/Busan Balgeunsesang eye clinic announce strategic cooperation agreement

15 Aug 2017

BRIEF-Staar Surgical Q2 loss per share $0.02

* Q2 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

03 Aug 2017

Earnings vs. Estimates